Liqui Dex 30mL 1mg/mL

LiquiDex / LiquiDex / Liquidex (Dex) is an aromatase inhibitor (AI). An AI is in a class of drugs used for the treatment of breast cancer and ovarian cancer by lowering estrogen.

Dex has also been utilized in off-label use to treat or prevent Gynaecomastia in male test subjects with un-normal hormone levels or that have been administered superalogical (high, un-normal) levels of androgenic hormones. In this case Dex is used to keep estrogen low-normal while keeping other wanted androgen levels high.

Dex shows much of its positive effects in research due to its estrogen lowering capabilities and has been shown in research studies to lessen and/or prevent Edema (bloating), high blood pressure (BP) and Gynaecomastia (breast tissue growth in men). This works for Dex when estrogen levels may be higher in the body due to other factors. Dex does this very effectively and has been shown to be well tolerated in test subjects.

We are proud to offer you only the highest quality Dex available for all your research needs!


REF:
1) Variation in LiquiDex metabolism and pharmacodynamics in women with early breast cancer.Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM. http://www.ncbi.nlm.nih.gov/pubmed/20354183
2) Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative LiquiDex or Liquid Tamox.Fujiwara Y, Takatsuka Y, Imoto S, Inaji H, Ikeda T, Akiyama F, Tamura M, Miyoshi K, Iwata H, Mitsuyama S, Noguchi S. http://www.ncbi.nlm.nih.gov/pubmed/22136317
3) Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios.Gregoriou O, Bakas P, Grigoriadis C, Creatsa M, Hassiakos D, Creatsas G. http://www.ncbi.nlm.nih.gov/pubmed/22579129
4) Pharmacokinetic comparison of 2 formulations of LiquiDex (1 mg) in healthy Korean male volunteers: a randomized, single-dose, 2-period, 2-sequence, crossover study.Noh YH, Ko YJ, Cho SH, Ghim JL, Choe S, Jung JA, Kim UJ, Jin SJ, Park HJ, Song GS, Lim HS, Bae KS. http://www.ncbi.nlm.nih.gov/pubmed/22281018